GENFIT Reports Strong 2024 Financial Results with First Commercial Revenues from Iqirvo®
GENFIT reported a net profit of €1.5 million for 2024, driven by €67.0 million in revenues including a €48.7 million milestone payment and royalties from Iqirvo® (elafibranor) sales in PBC.
Ipsen's Elafibranor Shows Promise in Phase II Trial for Primary Sclerosing Cholangitis
Elafibranor demonstrated a favorable safety profile and significant dose-dependent efficacy in the Phase II ELMWOOD trial for primary sclerosing cholangitis (PSC), a rare liver disease with no currently approved treatments.
Ipsen Secures Dual CHMP Approvals for Rare Liver Disease Treatments Following Regulatory Strategy Shift
Ipsen received CHMP approval for odevixibat under the new brand name Kayfanda for Alagille syndrome, marking the second approval for the same drug after rebranding due to orphan status complications.
Madrigal's Resmetirom Shows Promise in NASH Treatment Where Others Have Failed
Madrigal Pharmaceuticals' resmetirom demonstrated significant efficacy in the Phase 3 MAESTRO-NASH trial, achieving both primary endpoints of NASH resolution and liver fibrosis improvement.
GENFIT Secures €185 Million Royalty Financing Deal with HCRx, Restructures Convertible Debt
GENFIT has successfully completed a non-dilutive royalty financing agreement with HCRx worth up to €185 million, receiving an immediate €130 million upfront payment with potential for an additional €55 million upon achieving near-term milestones.
Isomorphic Labs Secures $600M to Advance AI-Powered Drug Discovery Platform
Isomorphic Labs raised $600 million in its first external funding round in March 2025, representing the largest private biotech investment of the month.
NorthSea Therapeutics Strengthens Executive Team with Strategic CFO and CMO Appointments
NorthSea Therapeutics appoints Melissa Bradford-Klug as CFO/CBO, bringing over 20 years of experience and $6 billion in financing track record to advance metabolic disease therapies.
FDA Grants Accelerated Approval to Ipsen's Iqirvo, First Dual PPAR Agonist for Primary Biliary Cholangitis
Ipsen's Iqirvo (elafibranor) receives FDA accelerated approval as the first dual PPAR alpha/delta agonist and first new therapy in over a decade for primary biliary cholangitis treatment.
Advanced Liver Cancer Market to Reach $11.13 Billion by 2035, Driven by Early Detection and Novel Therapies
The advanced liver cancer market is projected to grow from $2.31 billion in 2024 to $11.13 billion by 2035, exhibiting a CAGR of 15.38%, according to IMARC Group research.
Iqirvo (Elafibranor) Shows Sustained Efficacy and Safety in Long-Term PBC Treatment
Interim data from the open-label extension of the Phase III ELATIVE trial demonstrate Iqirvo's sustained efficacy and safety profile for up to three years in patients with primary biliary cholangitis (PBC).